Vaxcyte, Inc. $PCVX Shares Bought by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Vaxcyte, Inc. by 7.7% in Q1, owning 1,255,827 shares valued at approximately $47.4 million.
• Analysts are optimistic about Vaxcyte, with a consensus rating of "Buy" and a price target of $136.50, following a strong buy rating from ten analysts.
• Vaxcyte reported a loss of ($1.22) earnings per share for the latest quarter, falling short of the consensus estimate of ($1.12).

Invesco Ltd. raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 7.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,255,827 shares of the company's stock after acquiring an additional 89,773 shares during the period. Invesco Ltd. owned approximately 0.97% of Vaxcyte worth $47,420,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Bridgefront Capital LLC grew its stake in shares of Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after purchasing an additional 172 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares during the period. Avior Wealth Management LLC grew its stake in shares of Vaxcyte by 5.3% during the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock worth $257,000 after purchasing an additional 343 shares during the period. US Bancorp DE grew its stake in shares of Vaxcyte by 7.2% during the 1st quarter. US Bancorp DE now owns 5,344 shares of the company's stock worth $202,000 after purchasing an additional 357 shares during the period. Finally, Xponance Inc. grew its stake in shares of Vaxcyte by 4.7% during the 1st quarter. Xponance Inc. now owns 9,320 shares of the company's stock worth $352,000 after purchasing an additional 415 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Performance

NASDAQ PCVX traded up $0.5050 during trading hours on Thursday, reaching $31.7650. The company's stock had a trading volume of 619,936 shares, compared to its average volume of 1,768,129. The stock has a market cap of $4.12 billion, a PE ratio of -7.73 and a beta of 1.21. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The company's 50-day moving average is $33.74 and its two-hundred day moving average is $45.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the prior year, the business earned ($1.10) EPS. Equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.